IO, Jakarta, 4 March 2021 – PT CKD OTTO Pharmaceuticals, a pharmaceutical company specializing in oncology products announced today that they are signing business collaboration contract with Saidal Group, an Algerian State-Owned Enterprise and one of the leading pharmaceutical company in Algeria, since its first MOU with Saidal in December 2020.
Due to Covid-19 pandemic, the signing ceremony was held via online. And the event was attended by Mrs. Fatoum Akachem, the CEO of Saidal Group and Mr. In Hyun Baik, the President Director of CKD OTTO, together with Dr. Penny K. Lukito, MCP, the Head of Indonesia National Agency of Drug and Food Control.
Mrs. Dr. Penny K. Lukito, MCP, the head of Indonesia NADFC has said in her speech during the signing ceremony, “We all know that cancer is a disease that continues to increase in prevalence, globally. The data in Indonesia shows, quoted from the basic health research from the Ministry of Health, showing an increase in the prevalence of tumors or cancer from 1.4 out of 1,000 population in 2013 to 1.8 out of 1,000 population in 2018. This shows an increase. Meanwhile globally, from the GLOBOCAN (Global Cancer Observatory), an interactive web-based platform that presents the global statistics of cancer-related control and research, data obtained in 2020, there were 19.3 million new cancer cases globally with a high mortality rate, which is 10 million deaths.”
These increased in prevalence shows that there is an increase demand for oncology medicines which needs to be answered. By the Agreement’s business model, CKD OTTO and SAIDAL Group set out to answer this needs. The business model will be started by exporting oncology products manufactured in Indonesia by CKD OTTO in bulk by the value of 18 million USD with 6 SKU’s during the next 3 years. In the second phase, technology transfer of these products will be performed once the manufacturing plant of Saidal Group for oncology medicine has been build.
Beside the availability of oncology medicines, product quality and customer preferences also need to be addressed. By investing more than 30 million USD for its production facility, CKD OTTO are manufacturing oncology products with a high standard. And since it became the first Halal-certified oncology factory in February 2019, it will reach 2 billion people in other Islamic countries and regulatory markets, including the Algeria’s pharmaceutical market, as it is in the 2nd position in terms of top 10 pharmaceutical markets in MENA (Middle East and North Africa) region with values of 4 billion USD.
In Hyun Baik, the President Director of PT CKD OTTO Pharmaceuticals has said that, “We hope that all the excellent medicines manufactured by the CKD OTTO will contribute towards the enhancement of health and welfare of all Indonesian citizens. Furthermore, we also hope to contribute towards the development and growth of the Asian economy, starting from Indonesia”.
About PT CKD OTTO Pharmaceuticals
PT CKD OTTO Pharmaceuticals was established on 14th September, 2015 with the vision to provide patients with better access to high-quality, cost-effective medicines in key therapeutic areas.
It obtained GMP Certificates in September 2018, for:
- Oncology Freeze Dry Injection
- Oncology Small Volume Injection
It also obtained Halal Certificate from Indonesian Ulema Council with Excellent category in February 2019.